A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer.
To evaluate the safety and feasibility of pre-operative locoregional cytokine therapy (IRX-2 regimen) in early stage breast cancer, and to evaluate for intratumoral and peripheral immunomodulatory activity. Sixteen patients with stage I-III early stage breast cancer (any histology type) indicated for surgical lumpectomy or mastectomy were enrolled to receive pre-operative locoregional immunotherapy with the IRX-2 cytokine biologic (2mL subcutaneous x 10 days to peri-areolar skin). The regimen also included single-dose cyclophosphamide (300mg/m2) on day 1 to deplete T-regulatory cells, and oral indomethacin to modulate suppressive myeloid subpopulations. The primary objective was to evaluate feasibility (i.e. receipt of therapy without surgical delays or grade III/IV treatment-related adverse events). The secondary objective was to evaluate changes in stromal tumor infiltrating lymphocyte score. The exploratory objective was to identify candidate pharmacodynamic changes for future study using a variety of assays including flow cytometry, RNA and T-cell receptor DNA sequencing, and multispectral immunofluroescence. Pre-operative locoregional cytokine administration was feasible in 100% (n=16/16) of subjects and associated with increases in stromal tumor-infiltrating lymphocytes (p<.001). Programmed death ligand 1 was upregulated at the RNA (p<.01) and protein level ((by Ventana PD-L1 (SP142) and immunofluorescence). Other immunomodulatory effects included upregulation of RNA signatures of T-cell activation and recruitment, and cyclophosphamide-related peripheral T-regulatory cell depletion. IRX-2 is safe in early stage breast cancer. Potentially favorable immunomodulatory changes were observed, supporting further study of IRX-2 in early stage breast cancer and other malignancies.